莫西沙星治疗慢性支气管炎细菌感染急性发作的临床疗效观察被引量：14

Observation of the clinical effect of Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis

下载PDF

导出

摘要目的:观察莫西沙星短疗程治疗慢性支气管炎细菌感染急性发作(ABECB)的临床疗效。方法:将74例ABECB患者随机分为两组,治疗组用莫西沙星400mg,po.qd,治疗5d;对照组用克拉霉素500mg,po.bid,治疗5d。观察临床指标、细菌学、临床疗效及安全性。结果:治疗组与对照组的有效率分别为91.9%和78.4%,细菌清除率为89.2%和75.7%,两组比较差异有显著性(P<0.05)。结论:莫西沙星在短疗程下治疗慢性支气管炎急性细菌加重的疗效显著,是一种广谱、安全的抗菌药物。 OBJECTIVE To compare the efficacy and safety of moxifloxacin with clarithromycin for the treatment of patients with acute bacterial exacerbations of chronic bronchitis （ABECB） in short course therapy. METItODS Seventy-four cases with ABECB were randomly divided into treatment group （moxifloxacin group） and control group （clarithromycin group）, with 37 cases in each group. The efficacy and safety of the two groups were investigated. RESULTS The effective rate and bacteria eradication rate were 91.9% and 89. 2% respectively in moxifloxacin group and 78. 4% and 75.7% respectively in clarithromycin group, with significant difference between them（P〈0. 05）. CONCLUSION Moxifloxacin is a broad-spectrum and safe antibiotic and has significant effect in short course therapy for the treatment of acute bacterial exacerbations of chronic bronchitiS, and can be taken as the first choice drug on this disease.

作者蔡绚于小红程竹

机构地区贵阳医学院附属医院

出处《中国医院药学杂志》 CAS CSCD 北大核心 2008年第3期221-223,共3页 Chinese Journal of Hospital Pharmacy

关键词莫西沙星慢性支气管炎细菌感染急性发作短疗程治疗 moxifloxacin ABECB Short-course therapy

分类号 R978 [医药卫生—药品]

引文网络
相关文献

参考文献4

1Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis[J]. Chest, 2000. 117 (Suppl) : 3801.
2中华人民共和国卫生部药政局.新药(西药)临床研究指导原则汇编.1993.51-53.
3马伟斌,江荣林,毛文炜.莫西沙星治疗慢性支气管炎急性发作的前瞻性研究[J].药学实践杂志,2005,23(1):30-32. 被引量：17
4Gallup Organization. Consumer attiudes toward antibiotic use [J]. New York: American Lung Association. 1995: moxifloxacin 5- day therapy bronchitis 27.

二级参考文献7

1Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis[J]. Chest,2000,117 ( Suppl 2 ):380s.
2Anthonisen NR, Manfreda J, Warren CP,et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease[J]. Ann Intern Med, 1987,106:196
3Stass H, Dalhoff A, Kubitza D,et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8 - methoxy guinolone, administered to healthy subjects[J]. Antimicrob Agents Chemother, 1998,42:2060.
4Richarx W. Moxifloxacin clinical pharmacology[J]. Clin Drug,1999,17(5) :365.
5Andrews J, Honeybourue D, Jevons G, et al. Penetration of moxifloxacin into bronchial mucosa, epithelial lining fluid and alveolar macrophages following a single 400mg oral dose[C]. 38th Int Conf Antimicrob Agents Chemother, 1998:Abstract A29.
6Bauer T, Landen H. Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis[J]. Clin Drug Invest,2002,22(10):641.
7Chodosh S,De Abate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis[J]. Respir Med,2000 Jan,94(1):17.